BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7636204)

  • 1. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
    Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
    J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
    Tahara H; Zitvogel L; Storkus WJ; Zeh HJ; McKinney TG; Schreiber RD; Gubler U; Robbins PD; Lotze MT
    J Immunol; 1995 Jun; 154(12):6466-74. PubMed ID: 7759882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
    Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
    Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
    Eguchi J; Hiroishi K; Ishii S; Mitamura K
    Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer.
    Fernandez NC; Levraud JP; Haddada H; Perricaudet M; Kourilsky P
    J Immunol; 1999 Jan; 162(1):609-17. PubMed ID: 9886439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
    Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
    J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
    Nastala CL; Edington HD; McKinney TG; Tahara H; Nalesnik MA; Brunda MJ; Gately MK; Wolf SF; Schreiber RD; Storkus WJ
    J Immunol; 1994 Aug; 153(4):1697-706. PubMed ID: 7913943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
    Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
    Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
    Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
    Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction.
    Eguchi J; Hiroishi K; Ishii S; Baba T; Matsumura T; Hiraide A; Okada H; Imawari M
    Gene Ther; 2005 May; 12(9):733-41. PubMed ID: 15772692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.